Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment
Tóm tắt
Từ khóa
Tài liệu tham khảo
Welzel, 2006, Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra‐ and extrahepatic cholangiocarcinoma in the United States, J Natl Cancer Inst, 98, 873, 10.1093/jnci/djj234
Farley, 1995, “Natural history” of unresected cholangiocarcinoma: patient outcome after noncurative intervention, Mayo Clin Proc, 70, 425, 10.4065/70.5.425
Shaib, 2004, The epidemiology of cholangiocarcinoma, Semin Liver Dis, 24, 115, 10.1055/s-2004-828889
McLean, 2006, Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States, Liver Int, 26, 1047, 10.1111/j.1478-3231.2006.01350.x
Shaib, 2004, Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?, J Hepatol, 40, 472, 10.1016/j.jhep.2003.11.030
Patel, 2001, Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States, HEPATOLOGY, 33, 1353, 10.1053/jhep.2001.25087
Mouzas, 2002, Increasing incidence of cholangiocarcinoma in Crete 1992‐2000, Anticancer Res, 22, 3637
Okuda, 2002, Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment, J Gastroenterol Hepatol, 17, 1056, 10.1046/j.1440-1746.2002.02780.x
Yoon, 2004, Oxysterols induce cyclooxygenase‐2 expression in cholangiocytes: implications for biliary tract carcinogenesis, HEPATOLOGY, 39, 732, 10.1002/hep.20125
Burak, 2004, Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis, Am J Gastroenterol, 99, 523, 10.1111/j.1572-0241.2004.04067.x
Bergquist, 2002, Hepatic and extrahepatic malignancies in primary sclerosing cholangitis, J Hepatol, 36, 321, 10.1016/S0168-8278(01)00288-4
Watanapa, 2002, Liver fluke‐associated cholangiocarcinoma, Br J Surg, 89, 962, 10.1046/j.1365-2168.2002.02143.x
Kurathong, 1985, Opisthorchis viverrini infection and cholangiocarcinoma. A prospective, case‐controlled study, Gastroenterology, 89, 151, 10.1016/0016-5085(85)90755-3
Tesana, 2000, Ultrastructural and immunohistochemical analysis of cholangiocarcinoma in immunized Syrian golden hamsters infected with Opisthorchis viverrini and administered with dimethylnitrosamine, Parasitol Int, 49, 239, 10.1016/S1383-5769(00)00052-0
Parkin, 1991, Liver cancer in Thailand. I. A case‐control study of cholangiocarcinoma, Int J Cancer, 48, 323, 10.1002/ijc.2910480302
Kubo, 1995, Hepatolithiasis associated with cholangiocarcinoma, World J Surg, 19, 637, 10.1007/BF00294744
Lesurtel, 2002, Intrahepatic cholangiocarcinoma and hepatolithiasis: an unusual association in Western countries, Eur J Gastroenterol Hepatol, 14, 1025, 10.1097/00042737-200209000-00016
Su, 1997, Hepatolithiasis associated with cholangiocarcinoma, Br J Surg, 84, 969, 10.1002/bjs.1800840717
Chapman, 1999, Risk factors for biliary tract carcinogenesis, Ann Oncol, 10, 308, 10.1093/annonc/10.suppl_4.S308
Lipsett, 1994, Choledochal cyst disease. A changing pattern of presentation, Ann Surg, 220, 644, 10.1097/00000658-199411000-00007
Scott, 1980, Bile duct carcinoma: a late complication of congenital hepatic fibrosis. Case report and review of literature, Am J Gastroenterol, 73, 113
Shaib, 2007, Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital‐based case‐control study, Am J Gastroenterol, 102, 1016, 10.1111/j.1572-0241.2007.01104.x
Tocchi, 2001, Late development of bile duct cancer in patients who had biliary‐enteric drainage for benign disease: a follow‐up study of more than 1,000 patients, Ann Surg, 234, 210, 10.1097/00000658-200108000-00011
Bettschart, 2002, Cholangiocarcinoma arising after biliary‐enteric drainage procedures for benign disease, Gut, 51, 128, 10.1136/gut.51.1.128
Walker, 2005, Dose‐additive carcinogenicity of a defined mixture of “dioxin‐like compounds”, Environ Health Perspect, 113, 43, 10.1289/ehp.7351
Nomoto, 2006, Intrahepatic cholangiocarcinoma arising in cirrhotic liver frequently expressed p63‐positive basal/stem‐cell phenotype, Pathol Res Pract, 202, 71, 10.1016/j.prp.2005.10.011
Sell, 1989, Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma, Am J Pathol, 134, 1347
Jaiswal, 2001, Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis, Am J Physiol Gastrointest Liver Physiol, 281, G626, 10.1152/ajpgi.2001.281.3.G626
Jaiswal, 2000, Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide‐dependent mechanism, Cancer Res, 60, 184
Jaiswal, 2001, Human Ogg1, a protein involved in the repair of 8‐oxoguanine, is inhibited by nitric oxide, Cancer Res, 61, 6388
Dergham, 1997, Prevalence and clinical significance of combined K‐ras mutation and p53 aberration in pancreatic adenocarcinoma, Int J Pancreatol, 21, 127, 10.1007/BF02822384
Z'Graggen, 1997, Prevalence of activating K‐ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas, Ann Surg, 226, 491, 10.1097/00000658-199710000-00010
Boberg, 2000, Cholangiocarcinoma in primary sclerosing cholangitis: K‐ras mutations and Tp53 dysfunction are implicated in the neoplastic development, J Hepatol, 32, 374, 10.1016/S0168-8278(00)80386-4
Furubo, 1999, Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma, Histopathology, 35, 230, 10.1046/j.1365-2559.1999.00705.x
Tannapfel, 2000, Frequency of p16(INK4A) alterations and K‐ras mutations in intrahepatic cholangiocarcinoma of the liver, Gut, 47, 721, 10.1136/gut.47.5.721
Ahrendt, 2000, p53 overexpression and K‐ras gene mutations in primary sclerosing cholangitis‐associated biliary tract cancer, J Hepatobiliary Pancreat Surg, 7, 426, 10.1007/s005340070039
Isa, 2002, Analysis of microsatellite instability, K‐ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma, Hepatogastroenterology, 49, 604
Watanabe, 1994, Point mutation of K‐ras gene codon 12 in biliary tract tumors, Gastroenterology, 107, 1147, 10.1016/0016-5085(94)90240-2
Tada, 1992, High incidence of ras gene mutation in intrahepatic cholangiocarcinoma, Cancer, 69, 1115, 10.1002/cncr.2820690509
Levi, 1991, Multiple K‐ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique, Cancer Res, 51, 3497
Kang, 1999, Mutation of p53 and K‐ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma, Lab Invest, 79, 477
Hahn, 1998, Mutations of the DPC4/Smad4 gene in biliary tract carcinoma, Cancer Res, 58, 1124
Taniai, 2002, p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC‐associated cholangiocarcinoma, Gastroenterology, 123, 1090, 10.1053/gast.2002.36021
Hodge, 2005, The role of IL‐6 and STAT3 in inflammation and cancer, Eur J Cancer, 41, 2502, 10.1016/j.ejca.2005.08.016
Sansone, 2007, IL‐6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland, J Clin Invest, 117, 3988, 10.1172/JCI32533
Gao, 2007, Mutations in the EGFR kinase domain mediate STAT3 activation via IL‐6 production in human lung adenocarcinomas, J Clin Invest, 117, 3846, 10.1172/JCI31871
Okada, 1994, Interleukin‐6 functions as an autocrine growth factor in a cholangiocarcinoma cell line, J Gastroenterol Hepatol, 9, 462, 10.1111/j.1440-1746.1994.tb01275.x
Goydos, 1998, Marked elevation of serum interleukin‐6 in patients with cholangiocarcinoma: validation of utility as a clinical marker, Ann Surg, 227, 398, 10.1097/00000658-199803000-00012
Yokomuro, 2000, Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non‐neoplastic biliary epithelial cells, HEPATOLOGY, 32, 26, 10.1053/jhep.2000.8535
Park, 1999, Inhibition of interleukin 6‐mediated mitogen‐activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line, HEPATOLOGY, 30, 1128, 10.1002/hep.510300522
Isomoto, 2007, Sustained IL‐6/STAT‐3 signaling in cholangiocarcinoma cells due to SOCS‐3 epigenetic silencing, Gastroenterology, 132, 384, 10.1053/j.gastro.2006.10.037
Isomoto, 2005, Interleukin 6 upregulates myeloid cell leukemia‐1 expression through a STAT3 pathway in cholangiocarcinoma cells, HEPATOLOGY, 42, 1329, 10.1002/hep.20966
Kobayashi, 2005, Interleukin‐6 contributes to Mcl‐1 up‐regulation and TRAIL resistance via an Akt‐signaling pathway in cholangiocarcinoma cells, Gastroenterology, 128, 2054, 10.1053/j.gastro.2005.03.010
Bodnar, 1998, Extension of life‐span by introduction of telomerase into normal human cells, Science, 279, 349, 10.1126/science.279.5349.349
Kim, 1994, Specific association of human telomerase activity with immortal cells and cancer, Science, 266, 2011, 10.1126/science.7605428
Ozaki, 1999, In situ nucleic acid detection of human telomerase in intrahepatic cholangiocarcinoma and its preneoplastic lesion, HEPATOLOGY, 30, 914, 10.1002/hep.510300419
Itoi, 2000, Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers, Gastrointest Endosc, 52, 380, 10.1067/mge.2000.108303
Iki, 1998, Increased telomerase activity in intrahepatic cholangiocellular carcinomas induced by N‐nitrosobis(2‐oxopropyl)amine in hamsters, Cancer Lett, 131, 185, 10.1016/S0304-3835(98)00148-7
Yamagiwa, 2006, Interleukin‐6 decreases senescence and increases telomerase activity in malignant human cholangiocytes, Life Sci, 78, 2494, 10.1016/j.lfs.2005.10.015
Tadlock, 2001, Involvement of p38 mitogen‐activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line, HEPATOLOGY, 33, 43, 10.1053/jhep.2001.20676
Wehbe, 2006, Interleukin‐6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression, Cancer Res, 66, 10517, 10.1158/0008-5472.CAN-06-2130
Yoon, 2004, Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells, J Hepatol, 41, 808, 10.1016/j.jhep.2004.07.016
Werneburg, 2003, Bile acids activate EGF receptor via a TGF‐alpha‐dependent mechanism in human cholangiocyte cell lines, Am J Physiol Gastrointest Liver Physiol, 285, G31, 10.1152/ajpgi.00536.2002
Yoon, 2002, Bile acids induce cyclooxygenase‐2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line, Gastroenterology, 122, 985, 10.1053/gast.2002.32410
Endo, 2002, ERBB‐2 overexpression and cyclooxygenase‐2 up‐regulation in human cholangiocarcinoma and risk conditions, HEPATOLOGY, 36, 439, 10.1053/jhep.2002.34435
Han, 2004, Cyclooxygenase‐2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase‐2‐independent mechanism in celecoxib‐mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest, Cancer Res, 64, 1369, 10.1158/0008-5472.CAN-03-1086
Nzeako, 2002, COX‐2 inhibits Fas‐mediated apoptosis in cholangiocarcinoma cells, HEPATOLOGY, 35, 552, 10.1053/jhep.2002.31774
Ishimura, 2004, Inducible nitric oxide synthase upregulates cyclooxygenase‐2 in mouse cholangiocytes promoting cell growth, Am J Physiol Gastrointest Liver Physiol, 287, G88, 10.1152/ajpgi.00539.2003
Han, 2005, Cyclooxygenase‐2‐derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor‐mediated activation of the epidermal growth factor receptor and Akt, J Biol Chem, 280, 24053, 10.1074/jbc.M500562200
Wu, 2002, Involvement of 85‐kd cytosolic phospholipase A(2) and cyclooxygenase‐2 in the proliferation of human cholangiocarcinoma cells, HEPATOLOGY, 36, 363, 10.1053/jhep.2002.34743
Lai, 2005, erbB‐2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer, Gastroenterology, 129, 2047, 10.1053/j.gastro.2005.10.010
Aishima, 2002, c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma, Histopathology, 40, 269, 10.1046/j.1365-2559.2002.00353.x
Terada, 1998, Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis, Hum Pathol, 29, 175, 10.1016/S0046-8177(98)90229-5
Lai, 2000, Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated “intestinal‐type” biliary cancer chemically induced in rat liver, HEPATOLOGY, 31, 1257, 10.1053/jhep.2000.8108
Khan, 2002, Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document, Gut, 51, VI1, 10.1136/gut.51.suppl_6.vi1
Hann, 1996, Hepatic lobar atrophy: association with ipsilateral portal vein obstruction, AJR Am J Roentgenol, 167, 1017, 10.2214/ajr.167.4.8819404
Chen, 2002, The assessment of biliary CA 125, CA 19‐9 and CEA in diagnosing cholangiocarcinoma—the influence of sampling time and hepatolithiasis, Hepatogastroenterology, 49, 616
Nehls, 2004, Serum and bile markers for cholangiocarcinoma, Semin Liver Dis, 24, 139, 10.1055/s-2004-828891
Siqueira, 2002, Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis, Gastrointest Endosc, 56, 40, 10.1067/mge.2002.125105
Levy, 2005, The value of serum CA 19‐9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis, Dig Dis Sci, 50, 1734, 10.1007/s10620-005-2927-8
Patel, 2000, The utility of CA 19‐9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis, Am J Gastroenterol, 95, 204, 10.1111/j.1572-0241.2000.01685.x
Narimatsu, 1998, Lewis and secretor gene dosages affect CA19–9 and DU‐PAN‐2 serum levels in normal individuals and colorectal cancer patients, Cancer Res, 58, 512
Vestergaard, 1999, Reference values and biological variation for tumor marker CA 19‐9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population, Clin Chem, 45, 54
Akdogan, 2001, Extraordinarily elevated CA19–9 in benign conditions: a case report and review of the literature, Tumori, 87, 337, 10.1177/030089160108700513
Albert, 1988, Elevated serum levels of tumor marker CA19–9 in acute cholangitis, Dig Dis Sci, 33, 1223, 10.1007/BF01536670
Robledo, 1996, Extrahepatic bile duct carcinoma: US characteristics and accuracy in demonstration of tumors, Radiology, 198, 869, 10.1148/radiology.198.3.8628885
Slattery, 2006, What is the current state‐of‐the‐art imaging for detection and staging of cholangiocarcinoma?, Oncologist, 11, 913, 10.1634/theoncologist.11-8-913
Foley, 2007, The role of sonography in imaging of the biliary tract, Ultrasound Q, 23, 123, 10.1097/01.ruq.0000263851.53549.a5
Gores, 2000, Early detection and treatment of cholangiocarcinoma, Liver Transpl, 6, S30, 10.1053/jlts.2000.18688
Braga, 2001, MR imaging of intrahepatic cholangiocarcinoma: use of ferumoxides for lesion localization and extension, AJR Am J Roentgenol, 177, 111, 10.2214/ajr.177.1.1770111
Raman, 2001, Hepatic MR imaging using ferumoxides: prospective evaluation with surgical and intraoperative sonographic confirmation in 25 cases, AJR Am J Roentgenol, 177, 807, 10.2214/ajr.177.4.1770807
Gleeson, 2008, EUS‐guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma, Gastrointest Endosc, 67, 438, 10.1016/j.gie.2007.07.018
Malhi, 2006, Review article: the modern diagnosis and therapy of cholangiocarcinoma, Aliment Pharmacol Ther, 23, 1287, 10.1111/j.1365-2036.2006.02900.x
Petrowsky, 2006, Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma, J Hepatol, 45, 43, 10.1016/j.jhep.2006.03.009
Fritscher‐Ravens, 2001, FDG PET in the diagnosis of hilar cholangiocarcinoma, Nucl Med Commun, 22, 1277, 10.1097/00006231-200112000-00002
Corvera, 2008, 18F‐fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer, J Am Coll Surg, 206, 57, 10.1016/j.jamcollsurg.2007.07.002
Dumonceau, 2008, Grasp or brush for biliary sampling at endoscopic retrograde cholangiography? A blinded randomized controlled trial, Am J Gastroenterol, 103, 333, 10.1111/j.1572-0241.2007.01543.x
Alvaro, 2007, Serum and biliary insulin‐like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis, Ann Intern Med, 147, 451, 10.7326/0003-4819-147-7-200710020-00003
Baron, 2004, A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures, Clin Gastroenterol Hepatol, 2, 214, 10.1016/S1542-3565(04)00006-0
Halling, 2007, Fluorescence in situ hybridization in diagnostic cytology, Hum Pathol, 38, 1137, 10.1016/j.humpath.2007.04.015
Burke, 1998, Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system, Ann Surg, 228, 385, 10.1097/00000658-199809000-00011
Pichlmayr, 1996, Surgical treatment in proximal bile duct cancer. A single‐center experience, Ann Surg, 224, 628, 10.1097/00000658-199611000-00007
Klempnauer, 1997, Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors, J Clin Oncol, 15, 947, 10.1200/JCO.1997.15.3.947
Jarnagin, 2001, Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma, Ann Surg, 234, 507, 10.1097/00000658-200110000-00010
Casavilla, 1997, Hepatic resection and transplantation for peripheral cholangiocarcinoma, J Am Coll Surg, 185, 429, 10.1016/S1072-7515(01)00953-X
Lieser, 1998, Surgical management of intrahepatic cholangiocarcinoma: a 31‐year experience, J Hepatobiliary Pancreat Surg, 5, 41, 10.1007/PL00009949
Madariaga, 1998, Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases, Ann Surg, 227, 70, 10.1097/00000658-199801000-00011
Ohtsuka, 2002, Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival, Br J Surg, 89, 1525, 10.1046/j.1365-2168.2002.02268.x
Isaji, 1999, Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan, J Hepatobiliary Pancreat Surg, 6, 108, 10.1007/s005340050092
Valverde, 1999, Resection of intrahepatic cholangiocarcinoma: a Western experience, J Hepatobiliary Pancreat Surg, 6, 122, 10.1007/s005340050094
Nakeeb, 1996, Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors, Ann Surg, 224, 463, 10.1097/00000658-199610000-00005
Nathan, 2007, Trends in survival after surgery for cholangiocarcinoma: a 30‐year population‐based SEER database analysis, J Gastrointest Surg, 11, 1488, 10.1007/s11605-007-0282-0
Jarnagin, 2004, Surgical management of cholangiocarcinoma, Semin Liver Dis, 24, 189, 10.1055/s-2004-828895
Patel, 2006, Cholangiocarcinoma, Nat Clin Pract Gastroenterol Hepatol, 3, 33, 10.1038/ncpgasthep0389
Nagorney, 2006, Hepatic resection in the treatment of hilar cholangiocarcinoma, Adv Surg, 40, 159, 10.1016/j.yasu.2006.05.009
DeOliveira, 2007, Cholangiocarcinoma: thirty‐one‐year experience with 564 patients at a single institution, Ann Surg, 245, 755, 10.1097/01.sla.0000251366.62632.d3
Neuhaus, 1999, Extended resections for hilar cholangiocarcinoma, Ann Surg, 230, 808, 10.1097/00000658-199912000-00010
Kawarada, 2002, Surgical treatment of hilar bile duct carcinoma: experience with 25 consecutive hepatectomies, J Gastrointest Surg, 6, 617, 10.1016/S1091-255X(01)00008-7
Hemming, 2005, Surgical management of hilar cholangiocarcinoma, Ann Surg, 241, 693, 10.1097/01.sla.0000160701.38945.82
Gazzaniga, 2000, Surgery for hilar cholangiocarcinoma: an Italian experience, J Hepatobiliary Pancreat Surg, 7, 122, 10.1007/s005340050165
Abdalla, 2002, Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization, Arch Surg, 137, 675, 10.1001/archsurg.137.6.675
Makuuchi, 1990, Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report, Surgery, 107, 521
Nagino, 2006, Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long‐term follow‐up, Ann Surg, 243, 364, 10.1097/01.sla.0000201482.11876.14
McMasters, 1997, Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma, Am J Surg, 174, 605, 10.1016/S0002-9610(97)00203-1
Wiedmann, 2003, Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study, Cancer, 97, 2783, 10.1002/cncr.11401
Pascher, 2003, Intrahepatic cholangiocarcinoma: indication for transplantation, J Hepatobiliary Pancreat Surg, 10, 282, 10.1007/s00534-002-0731-9
O'Grady, 1988, Liver transplantation for malignant disease. Results in 93 consecutive patients, Ann Surg, 207, 373, 10.1097/00000658-198804000-00002
Pichlmayr, 1995, Role of liver transplantation in the treatment of unresectable liver cancer, World J Surg, 19, 807, 10.1007/BF00299775
Weimann, 2000, Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma, Br J Surg, 87, 1182, 10.1046/j.1365-2168.2000.01532.x
Meyer, 2000, Liver transplantation for cholangiocarcinoma: results in 207 patients, Transplantation, 69, 1633, 10.1097/00007890-200004270-00019
Iwatsuki, 1998, Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation, J Am Coll Surg, 187, 358, 10.1016/S1072-7515(98)00207-5
De Vreede, 2000, Prolonged disease‐free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma, Liver Transpl, 6, 309, 10.1053/lv.2000.6143
Sudan, 2002, Radiochemotherapy and transplantation allow long‐term survival for nonresectable hilar cholangiocarcinoma, Am J Transplant, 2, 774, 10.1034/j.1600-6143.2002.20812.x
Rea, 2005, Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma, Ann Surg, 242, 451, 10.1097/01.sla.0000179678.13285.fa
Heimbach, 2006, Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma, Transplantation, 82, 1703, 10.1097/01.tp.0000253551.43583.d1
Heimbach, 2004, Liver transplantation for unresectable perihilar cholangiocarcinoma, Semin Liver Dis, 24, 201, 10.1055/s-2004-828896
Gores, 2007, Cholangiocarcinoma: is transplantation an option? For whom?, J Hepatol, 47, 455, 10.1016/j.jhep.2007.07.003
Shepherd, 1988, Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial, Br J Surg, 75, 1166, 10.1002/bjs.1800751207
Andersen, 1989, Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice, Gut, 30, 1132, 10.1136/gut.30.8.1132
Smith, 1994, Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction, Lancet, 344, 1655, 10.1016/S0140-6736(94)90455-3
De Palma, 2001, Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study, Gastrointest Endosc, 53, 547, 10.1067/mge.2001.113381
Abu‐Hamda, 2004, Endoscopic management of cholangiocarcinoma, Semin Liver Dis, 24, 165, 10.1055/s-2004-828893
Kaassis, 2003, Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study, Gastrointest Endosc, 57, 178, 10.1067/mge.2003.66
Czito, 2006, Radiation therapy in the treatment of cholangiocarcinoma, Oncology (Williston Park), 20, 873
Foo, 1997, External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma, Int J Radiat Oncol Biol Phys, 39, 929, 10.1016/S0360-3016(97)00299-X
Pitt, 1995, Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival, Ann Surg, 221, 788, 10.1097/00000658-199506000-00017
Grove, 1991, Role of radiation after operative palliation in cancer of the proximal bile ducts, Am J Surg, 161, 454, 10.1016/0002-9610(91)91111-U
Krammer, 2001, Vascular effects of photodynamic therapy, Anticancer Res, 21, 4271
Korbelik, 1999, Photodynamic therapy‐mediated immune response against subcutaneous mouse tumors, Cancer Res, 59, 1941
Abels, 2004, Targeting of the vascular system of solid tumours by photodynamic therapy (PDT), Photochem Photobiol Sci, 3, 765, 10.1039/b314241h
Ortner, 2006, Technology insight: photodynamic therapy for cholangiocarcinoma, Nat Clin Pract Gastroenterol Hepatol, 3, 459, 10.1038/ncpgasthep0543
Ortner, 1998, Photodynamic therapy of nonresectable cholangiocarcinoma, Gastroenterology, 114, 536, 10.1016/S0016-5085(98)70537-2
Berr, 2000, Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival, HEPATOLOGY, 31, 291, 10.1002/hep.510310205
Ortner, 2003, Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study, Gastroenterology, 125, 1355, 10.1016/j.gastro.2003.07.015
Rumalla, 2001, Endoscopic application of photodynamic therapy for cholangiocarcinoma, Gastrointest Endosc, 53, 500, 10.1067/mge.2001.113386
Shim, 2005, Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment, Endoscopy, 37, 425, 10.1055/s-2005-861294
Harewood, 2005, Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma, J Gastroenterol Hepatol, 20, 415, 10.1111/j.1440-1746.2005.03582.x
Dumoulin, 2003, Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma, Gastrointest Endosc, 57, 860, 10.1016/S0016-5107(03)70021-2
Zoepf, 2005, Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy, Am J Gastroenterol, 100, 2426, 10.1111/j.1572-0241.2005.00318.x
Berr, 2004, Photodynamic therapy for cholangiocarcinoma, Semin Liver Dis, 24, 177, 10.1055/s-2004-828894
Nanashima, 2004, Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study, J Gastroenterol, 39, 1095, 10.1007/s00535-004-1449-z
Alberts, 2007, Treatment options for hepatobiliary and pancreatic cancer, Mayo Clin Proc, 82, 628, 10.4065/82.5.628
Falkson, 1984, Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer, Cancer, 54, 965, 10.1002/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X
Takada, 1994, Comparison of 5‐fluorouracil, doxorubicin and mitomycin C with 5‐fluorouracil alone in the treatment of pancreatic‐biliary carcinomas, Oncology, 51, 396, 10.1159/000227373
Choi, 2000, Effects of 5‐fluorouracil and leucovorin in the treatment of pancreatic‐biliary tract adenocarcinomas, Am J Clin Oncol, 23, 425, 10.1097/00000421-200008000-00023
Patt, 1996, Phase II trial of intravenous flourouracil and subcutaneous interferon alfa‐2b for biliary tract cancer, J Clin Oncol, 14, 2311, 10.1200/JCO.1996.14.8.2311
Patt, 2001, Phase II trial of cisplatin, interferon alpha‐2b, doxorubicin, and 5‐fluorouracil for biliary tract cancer, Clin Cancer Res, 7, 3375
Ducreux, 1998, Effective treatment of advanced biliary tract carcinoma using 5‐fluorouracil continuous infusion with cisplatin, Ann Oncol, 9, 653, 10.1023/A:1008241008379
Lee, 2004, Epirubicin, cisplatin, and protracted infusion of 5‐FU (ECF) in advanced intrahepatic cholangiocarcinoma, J Cancer Res Clin Oncol, 130, 346, 10.1007/s00432-003-0534-7
Taieb, 2002, Optimization of 5‐fluorouracil (5‐FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5‐FU and cisplatin (LV5FU2‐P regimen) in patients with biliary tract carcinoma, Ann Oncol, 13, 1192, 10.1093/annonc/mdf201
Raderer, 1999, Two consecutive phase II studies of 5‐fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer, Oncology, 56, 177, 10.1159/000011961
Jones, 1996, Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas, J Clin Oncol, 14, 2306, 10.1200/JCO.1996.14.8.2306
Kiba, 2006, Single‐agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature, Oncology, 70, 358, 10.1159/000098109
Scheithauer, 2002, Review of gemcitabine in biliary tract carcinoma, Semin Oncol, 29, 40, 10.1053/sonc.2002.37380
Escudier, 2007, Sorafenib in advanced clear‐cell renal‐cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655
Yu, 2005, The role of Mcl‐1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43‐9006, Oncogene, 24, 6861, 10.1038/sj.onc.1208841
Mott, 2007, mir‐29 regulates Mcl‐1 protein expression and apoptosis, Oncogene, 26, 6133, 10.1038/sj.onc.1210436
Nguyen, 2007, Small molecule obatoclax (GX15–070) antagonizes MCL‐1 and overcomes MCL‐1‐mediated resistance to apoptosis, Proc Natl Acad Sci U S A, 104, 19512, 10.1073/pnas.0709443104
Ishimura, 2005, Inducible nitric oxide synthase up‐regulates Notch‐1 in mouse cholangiocytes: implications for carcinogenesis, Gastroenterology, 128, 1354, 10.1053/j.gastro.2005.01.055
Jimeno, 2005, Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents, Cancer Res, 65, 3003, 10.1158/0008-5472.CAN-04-3586
Wiedmann, 2006, Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB‐2 tyrosine kinase inhibitor NVP‐AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib, Anticancer Drugs, 17, 783, 10.1097/01.cad.0000217433.48870.37
Zhang, 2004, Celecoxib‐induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation, HEPATOLOGY, 39, 1028, 10.1002/hep.20143
Wu, 2004, The cyclooxygenase‐2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells, Mol Cancer Ther, 3, 299, 10.1158/1535-7163.299.3.3
Date, 1998, Inhibition of tumor growth and invasion by a four‐kringle antagonist (HGF/NK4) for hepatocyte growth factor, Oncogene, 17, 3045, 10.1038/sj.onc.1202231
Sirica, 2002, Cyclooxygenase‐2 and ERBB‐2 in cholangiocarcinoma: potential therapeutic targets, Semin Liver Dis, 22, 303, 10.1055/s-2002-34507
Katayose, 1996, MUC1‐specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth, Cancer Res, 56, 4205
Ahn, 2002, IFN‐gammaupregulates apoptosis‐related molecules and enhances Fas‐mediated apoptosis in human cholangiocarcinoma, Int J Cancer, 100, 445, 10.1002/ijc.10516
Tanaka, 2000, Expression and antitumor effects of TRAIL in human cholangiocarcinoma, HEPATOLOGY, 32, 523, 10.1053/jhep.2000.9716
Thamavit, 1993, Promotion of cholangiocarcinogenesis in the hamster liver by bile duct ligation after dimethylnitrosamine initiation, Carcinogenesis, 14, 2415, 10.1093/carcin/14.11.2415
Imray, 1992, Induction of cholangiocarcinoma in the Golden Syrian hamster using methylazoxymethyl acetate, Eur J Surg Oncol, 18, 373
Radaeva, 1999, Overexpression of C‐NEU and C‐MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin‐producing cholangiocarcinoma, HEPATOLOGY, 29, 1453, 10.1002/hep.510290524
Xu, 2006, Induction of intrahepatic cholangiocellular carcinoma by liver‐specific disruption of Smad4 and Pten in mice, J Clin Invest, 116, 1843, 10.1172/JCI27282
Fava, 2005, gamma‐Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP‐dependent regulation of the protein kinase A/extracellular signal‐regulated kinase 1/2 pathway, Cancer Res, 65, 11437, 10.1158/0008-5472.CAN-05-1470
Marienfeld, 2003, Inhibition of cholangiocarcinoma growth by tannic acid, HEPATOLOGY, 37, 1097, 10.1053/jhep.2003.50192
Johnson, 2001, Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials, Br J Cancer, 84, 1424, 10.1054/bjoc.2001.1796
Voskoglou‐Nomikos, 2003, Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models, Clin Cancer Res, 9, 4227
Sausville, 2006, Contributions of human tumor xenografts to anticancer drug development, Cancer Res, 66, 3351, 10.1158/0008-5472.CAN-05-3627
Bibby, 2004, Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages, Eur J Cancer, 40, 852, 10.1016/j.ejca.2003.11.021
Maronpot, 1991, Furan‐induced hepatic cholangiocarcinomas in Fischer 344 rats, Toxicol Pathol, 19, 561, 10.1177/019262339101900401
Jan, 2004, Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma, Ann Surg, 240, 89, 10.1097/01.sla.0000129492.95311.f2
Yeh, 2004, Thioacetamide‐induced intestinal‐type cholangiocarcinoma in rat: an animal model recapitulating the multi‐stage progression of human cholangiocarcinoma, Carcinogenesis, 25, 631, 10.1093/carcin/bgh037
Farazi, 2006, Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53‐deficient mice, Cancer Res, 66, 6622, 10.1158/0008-5472.CAN-05-4609
Sirica, 2008, A novel “patient‐like” model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines, HEPATOLOGY, 47, 1178, 10.1002/hep.22088
Nakajima, 2003, Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S‐transferase‐pi‐specific inhibitor O1‐hexadecyl‐gamma‐glutamyl‐S‐benzylcysteinyl‐D‐phenylglycine ethylester, J Pharmacol Exp Ther, 306, 861, 10.1124/jpet.103.052696
ClinicalTrials.gov. List results for search of “cholangiocarcinoma”. Available at: http://clinicaltrials.gov/ct2/results?term=cholangiocarcinoma. Accessed January, 2008.